Iovance Biotherapeutics, Inc. is a pharmaceutical company based in the United States, specializing in personalized ESG therapies for cancer treatment. With a medium risk rating score of 28.2, the company is at the forefront of harnessing the human immune system to fight cancer cells. They are focused on developing and commercializing autologous T-cell therapy for solid tumor cancers, with the goal of becoming a leader in TIL therapies.